SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-23-086382
Filing Date
2023-11-14
Accepted
2023-11-14 06:05:34
Documents
83
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0923_allaritytherape.htm   iXBRL 10-Q 1462051
2 CERTIFICATION f10q0923ex31-1_allarity.htm EX-31.1 10264
3 CERTIFICATION f10q0923ex31-2_allarity.htm EX-31.2 10217
4 CERTIFICATION f10q0923ex32-1_allarity.htm EX-32.1 3622
5 CERTIFICATION f10q0923ex32-2_allarity.htm EX-32.2 3403
  Complete submission text file 0001213900-23-086382.txt   7339099

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE allr-20230930.xsd EX-101.SCH 77152
7 XBRL CALCULATION FILE allr-20230930_cal.xml EX-101.CAL 43955
8 XBRL DEFINITION FILE allr-20230930_def.xml EX-101.DEF 349216
9 XBRL LABEL FILE allr-20230930_lab.xml EX-101.LAB 681588
10 XBRL PRESENTATION FILE allr-20230930_pre.xml EX-101.PRE 367842
77 EXTRACTED XBRL INSTANCE DOCUMENT f10q0923_allaritytherape_htm.xml XML 815534
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41160 | Film No.: 231401342
SIC: 2834 Pharmaceutical Preparations